CHAPEL HILL - The National Cancer Institute has awarded a five-year, $13.6 million grant to the University of North Carolina at Chapel Hill's Carolina Center of Cancer Nanotechnology Excellence (C-CCNE) based at the UNC Lineberger Comprehensive Cancer Center, for research to improve the diagnosis and treatment of cancer through applying/using advances in nanotechnology. The grant will support the continued work of the center launched in 2005 as part of NCI's Alliance for Nanotechnology in Cancer. The C-CCNE, one of eight original centers in the national program, is one of nine that are funded in the new phase.
Joseph DeSimone, PhD, who will co-lead the C-CCNE research team along with Joel Tepper, MD, said, "Our efforts in nanomedicine show tremendous promise for improving the ways we detect and treat lung, brain, and breast cancer. We have refined our ability to make nanoparticles with unprecedented control and precision, and continued work in this area will reveal better approaches to targeting cancer cells with potent therapies while leaving healthy cells intact.
DeSimone is Chancellor's Eminent Professor of Chemistry in UNC's College of Arts and Sciences. Tepper is the Hector MacLean Distinguished Professor of Cancer Research and former chair of radiation oncology.
UNC Lineberger Director, Shelley Earp, MD, is enthusiastic, "The renewal of the award is a tribute to the world-class combination of the physical, biological, and medical science possible at UNC's Cancer Center and the collaboration among the leaders and principal investigators including Otto Zhou, Leaf Huang, Russ Mumper and their colleagues."
"The synthesis of physics, chemistry, cell biology, animal models and clinical science is extraordinary," he added.
DeSimone explained, "Collaboration is fundamental to our success. Our multidisciplinary team of chemists, physicists, biologists, engineers, and clinicians drive our innovations in science. Our pa
|Contact: Dianne Shaw|
University of North Carolina School of Medicine